Cian Healthcare Reports FY26 Results Post-CIRP

Cian Healthcare Limited has announced its audited financial results for the year ended March 31, 2026, marking a significant transition following the National Company Law Tribunal (NCLT) approved Resolution Plan. New management took control on February 1, 2026.

Standalone FY26 Income: ₹28.30 crore
Consolidated FY26 Loss: ₹23.29 crore

Reader Takeaway: CIRP completed, but qualified audit signals ongoing governance challenges for new management.

What Just Happened

Cian Healthcare reported a consolidated net loss of ₹23.29 crore for the fiscal year 2026. The company's total income stood at ₹29.47 crore. These results come after the implementation of a Resolution Plan approved by the NCLT and a change in management on February 1, 2026.

Why This Matters

The qualified audit opinion highlights several critical issues that investors must be aware of. These include difficulties in verifying trade receivables, advances, and deposits, a lack of physical verification for property, plant, and equipment, and discrepancies in inventory valuation. Furthermore, the auditors noted insufficient documentation regarding Internal Financial Controls over Financial Reporting (IFCFR).

The company's subsidiary, Dr. Smith's Biotech Private Limited, is also under CIRP, with its auditor issuing a Disclaimer of Opinion due to halted operations and going concern uncertainty.

The Backstory

Cian Healthcare Limited underwent a Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code (IBC). The NCLT-approved Resolution Plan involved capital restructuring, including the cancellation of existing equity and issuance of fresh equity, resulting in a revised paid-up capital of ₹25 crore. Additionally, new management infused ₹13.55 crore as unsecured loans at 7.3% interest.

What Changes Now

The company has undergone a significant balance sheet cleanup. The focus will now shift to the new management's efforts to rectify internal control weaknesses, reconcile outstanding balances, and improve operational performance. The infusion of capital and restructuring aims to provide a stable foundation for future operations.

Risks to Watch

The qualified audit opinion is a significant governance watch point. Investors need to monitor the company's progress in addressing the documentation gaps, improving internal controls, and resolving issues related to its subsidiary. The effectiveness of the new management in reviving operational performance is crucial.

Peer Comparison

While specific peer data for companies emerging from CIRP with qualified audit opinions is limited, the sector generally faces scrutiny over governance and operational turnaround post-restructuring.

Context Metrics (Time-bound)

• Consolidated Income (FY26): ₹29.47 crore
• Consolidated Net Loss (FY26): ₹23.29 crore
• Total Assets (Consolidated FY26): ₹61.55 crore
• Revised Paid-up Capital: ₹25 crore
• Loan Infusion: ₹13.55 crore
• Interest Rate on New Loans: 7.3% per annum
• Management Change Date: February 1, 2026

What to Track Next

Investors should closely watch the company's quarterly results, management commentary on addressing audit qualifications, and any signs of operational recovery. The ability to strengthen internal controls and provide clear, verifiable financial data will be key indicators.